Production of 2'3'-cyclic gmp-amp (CGAMP) and method of use thereof

WO2024178279A3PCT designated stage expired Publication Date: 2024-11-28THE REGENTS OF THE UNIVERSITY OF COLORADO
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/016988
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-02-24
Filing Date
2024-02-23
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

There is a long-felt need for a simple, inexpensive, and effective system to biosynthesize 2’3’-cGAMP independent of cGAS-directed synthesis, which can be used as a therapeutic compound to activate the STING pathway in vivo, particularly for anticancer immune responses.

Method used

The synthesis of 2’3’-cGAMP is achieved through the action of nucleotidyltransferase 5 (NTase05) enzymes, with specific proteins catalyzing the production from ATP and GTP components, allowing for the generation of this cyclic dinucleotide without relying on cGAS or cytosolic DNA stimulation, and can be administered via genetically engineered host cells that biosynthesize and deliver 2’3’-cGAMP to activate the STING pathway.

Benefits of technology

This approach enables the independent production and delivery of 2’3’-cGAMP, acting as a potent STING agonist, potentially enhancing anticancer immune responses and providing a therapeutic option for conditions treatable through STING activation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000001
    Figure 000001
  • Figure 000002
    Figure 000002
  • Figure 000003
    Figure 000003
Patent Text Reader

Abstract

The preset invention is directed to systems, methods, and composition for the synthesis of 2'3'- cGAMP.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] PRODUCTION OF 2’3’-CYCLIC GMP-AMP (cGAMP) AND METHOD OF USE THEREOF

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This International PCT application claims the benefit of and priority to U.S. Provisional Application No. 63 / 486,766 filed February 24, 2023, the specification, claims and drawings of which are incorporated herein by reference in their entirety.

[0004] STATEMENT OF GOVERNMENT INTEREST

[0005] This invention was made with government support under grant number AT012346 awarded by the National Institutes of Health. The government retains certain rights in this invention.

[0006] SEQUENCE LISTING

[0007] The instant application contains contents of the electronic sequence listing (90245.00971- Sequence Listing. xml; Size: 8,843 bytes; and Date of Creation: February 22, 2024) is herein incorporated by reference in its entirety.

[0008] TECHNICAL FIELD

[0009] The inventive technology is directed to the field of chemical synthesis, and in particular novel system., methods, and compositions for the in vivo production of 2’3’-Cyclic-GMP-AMP (2’3’-cGAMP).

[0010] BACKGROUND

[0011] The human cGAS-cGAMP-STING pathway links detection of DNA in the cytoplasm with a potent antimicrobial and anticancer immune response. (See FIG. 1) When cGAS binds DNA localized outside the nucleus it synthesizes the nucleotide second messenger 2’3 ’-cGAMP, which diffuses throughout the cell. 2’3’-cGAMP, also referred to herein as cGAMP, binds STING which activates a signaling cascade resulting in type I interferon activation, NF-KB-mediated inflammation, autophagy, and cell death. STING signaling was discovered in the context of infection, where this pathway links detection of pathogen DNA to antiviral and antibacterial signaling. However, the cGAS-cGAMP-STING pathway has recently gained attention for its pivotal role in anti cancer signaling. Mice deficient in either cGAS or STING are unable to mount anticancer immune responses. In addition, the activity of some anticancer therapeutics, such as immune checkpoint inhibitors, are dependent on cGAS and STING. These findings spotlight the important role of cGAS-cGAMP-STING in disease. Cyclic dinucleotides, like 2’3’-cGAMP are enzymatically synthesized by joining two nucleotide triphosphates (in this case from ATP and GTP). The phosphodiester bonds linking the nucleotides can be either 3 ’-5’ linked such as in RNA and DNA, or 2’-5’ linked, a comparatively rare bond in biology. 2’3’- cGAMP is asymmetric with one 2’ bond and one 3’ bond, giving the name 2’3’-cGAMP. Nucleotides are ideal second messengers because they are synthesized from abundant precursor NTPs and rapidly alter cellular signaling by binding specific receptors (e.g. STING). Given four abundant ribonucleotide triphosphates and different phosphodiester bonds, many cyclic dinucleotides are possible. Cyclic dinucleotides like 2’3’-cGAMP are also highly stable, which enables both intracellular signaling and uptake of these molecules from the extracellular space. 2’3’-cGAMP was discovered in 2013 as the first and only cyclic dinucleotide in mammalian cells.

[0012] As such, there exists a long-felt need for a simple, inexpensive, and effective system biosynthesize 2’ 3 ’-cGAMP independent of cGAS-directed synthesis, which can further be isolated and used as a therapeutic compound, such as a STING agonist. There furthers exists a long-felt need for a host cell, such as a bacterial probiotic or other similar host, that can be genetically engineered to biosynthesize 2’3’-cGAMP. This host cell can be administered to a subject in need thereof, and biosynthesize and deliver a therapeutically effective amount 2’ 3 ’-cGAMP to the subject and thereby activate the STING-pathway in vivo.

[0013] SUMMARY OF THE INVENTION

[0014] The preset invention is directed to systems, methods, and composition for the synthesis of 2’ 3 ’-cGAMP. In one aspect, synthesis of 2’3 ’-cGAMP is through the action of one or more proteins generally referred to herein as a nucleotidyltransferase 5 (NTase05 or CD-NTase) enzyme.

[0015] In one aspect, a protein comprising an amino acid sequence having at least 70% sequence identity with any one of the NTase05 amino acid sequences listed in Table 1 catalyzes the production of 2’ 3 ’-cGAMP from its constituents ATP and GTP components.

[0016] In one aspect, the production of 2’3 ’-cGAMP from its constituents ATP and GTP components independent of the action of cGAS or in response to cytosolic DNA stimulation.

[0017] In certain aspects, the NTase05 enzyme of the invention can include a modified polypeptide, and may further be selected from the sequences according to SEQ ID NOs. 1-6, , or a biologically active fragment thereof. In another aspect, a NTaseO5 protein of the invention includes a modified peptide having a heterologous portion selected from the group consisting of: a signal peptide, a peptide tag, a dimerization domain, an oligomerization domain, an antibody, or an antibody fragment. In still further embodiments the peptide tag is a thioredoxin, Maltose-binding protein (MBP), SUM02, Glutathione-S-Transferase (GST), calmodulin binding protein (CBP), protein C tag, Myc-tag, Halo-Tag, HA tag, Flag tag, His tag, biotin lag, V5 tag, or OmpA signal sequence tag. In still another embodiment, the antibody fragment is an Fe domain. In yet another embodiment, the polypeptide is immobilized on an object selected from the group consisting of a cell, a metal, a resin, a polymer, a ceramic, a glass, a microelectrode, a graphitic particle, a bead, a gel, a plate, an array, and a capillary tube.

[0018] In yet another aspect, an isolated nucleic acid molecule comprising a nucleotide sequence, which is complementary to a nucleic acid sequence described herein, is provided. In another aspect, a vector, such as an expression vector, comprising a nucleic acid molecule described herein, is provided.

[0019] In still another aspect, a host cell transfected , with an expression vector described herein, is provided.

[0020] In yet another aspect, a method of producing a polypeptide described herein, comprising culturing a host cell described herein in an appropriate culture medium to, thereby, producing the polypeptide, is provided.

[0021] In yet another aspect, a method of producing a 2’3’-cGAMP is described herein, comprising culturing a host cell described herein in an appropriate culture medium to, thereby, producing the polypeptide, which in turn biosynthesizes 2’3’-cGAMP, which can further be isolated and administered as a STING agonist, preferably as a pharmaceutical composition, and more preferably to a subject in need thereof.

[0022] In still another aspect, a non-human animal model engineered to express a polypeptide described herein, is provided. In one embodiment, the polypeptide is overexpressed . In another embodiment, the animal is a knock-in or a transgenic animal. In still another embodiment, thee animal is a rodent.

[0023] In yet another aspect, a method of synthesizing nucleotides, and preferably 2’3’-cGAMP, comprising contacting a polypeptide described herein, or biologically active fragment thereof, with nucleotide substrates in vitro, ex vivo, or in vivo. In yet another aspect, a method of producing a 2’3’-cGAMP is described herein, comprising culturing a host cell described herein in an appropriate culture medium to, thereby, producing the polypeptide, which in turn biosynthesizes 2’3’-cGAMP, wherein the host cell can be administered preferably as a pharmaceutical or probiotic composition, and more preferably to a subject in need thereof, wherein the 2’3’-cGAMP by the host cell acts as a STRONG agonist.

[0024] Additional aspects of the inventive technology will be evident from the detailed description and figures presented below.

[0025] BRIEF DESCRIPTION OF THE FIGURES

[0026] FIG 1. The human cGAS-cGAMP-STING pathway. Cyclic GMP-AMP Synthase (cGAS) binds double stranded DNA to synthesize 2’,3’-cyclic GMP-AMP (2’3’-cGAMP), activating Stimulator of Interferon Genes (STING). STING signaling is crucial for immune system and anticancer signaling.

[0027] FIGS 2A-F. Novel discovery of bacterial CD-NTase enzymes that produce 2', 3'- cGAMP: (a) Thin layer chromatography (TLC) of cyclic oligonucleotides produced by diverse bacterial CD-NTase enzymes across all clades (reproduced from Whiteley et al., Nature 2019). (b) The arrow indicates treatment of the products with Pl endonuclease, which specifically cleaves 3 '-5' linked phosphodiester bonds. This TLC demonstrates reaction products that were resistant to Pl cleavage indicating the presence of a 2'-5' linked phosphodiester bond such as in 2',3'-cGAMP. (c) Confirmation that CD-NTase005 (sometimes referred to as CD-NTase) uses ATP and GTP as substrates, whereas CD-NTase036 uses ATP exclusively, thus excluding 2'3'-cGAMP as its reaction product. Radiolabeled NTP precursors were used in CD-NTase reactions, and the product formed by CD-NTase005 uses ATP and GTP. (d) CD-NTase reactions using homologues of CD- NTase005 in the presence of increasing manganese. CD-NTase005-03 from Bacillus thuringiensis 407 forms a product that appears to be 2',3'-cGAMP, accelerated by the presence of manganese, (e) 2',3'-cGAMP specific ELISA (Arbor Assays) to confirm the identity of the reaction product. In this panel, Synthetic cGAMP from all four isoforms as well as linear 2',5'-pppGpA, cyclic diAMP, and cyclic di-GMP were tested for cross-reactivity as controls, only 2', 3 '-cGAMP gives a detectable signal using this assay, (f) CD-NTase reaction products from CD-NTaseOO5-O3 {Bacillus thuringiensis (Bt) and CD-NTase005-05 {Clostridium botulinum (Cb)) were confirmed to produce 2'3 '-cGAMP via the same ELISA assay described in le. Reactions were also treated with VacV poxin enzyme or Pl endonuclease for one hour which convert 2'3'-cGAMP into a linear product which is not detected by the ELISA. In the poxin or Pl -treated samples, the signal was significantly reduced compared to the untreated reaction, indicating that the product is 2', 3'- cGAMP. Recombinantly purified human cGAS which exclusively produces 2',3'-cGAMP was used as a control. Like the bacterial CD-NTases 005-03 and 005-05, the product is 2',3'-cGAMP which are sensitive to poxin and Pl treatment.

[0028] FIG 3. Measuring 2’3’-cGAMP in cellular lysates. ChimeralO displays higher activity, reflecting a higher 2’3’-cGAMP concentration, in lysate derived from WT CdnB expressed during phage infection, as compared to a catalytically dead strain or an empty vector. The present inventors demonstrated the measurement of 2 / 3 / -cGAMP in cellular lysates. Specifically, B. subtilis PY79 expressing Empty vector (EV), BtCBASS system, or BtCBASS CdnB-Catalytically dead were grown in 200 ml of LB + phage salts (, and infected with phage SPP1 at an MOI of 2. Cells were harvested 40 minutes post infection, concentrated, and resuspended in 400 pl of water. Bacteria were lysed via bead beating, boiled for 20 minutes, and cellular debris was removed by centrifugation. The supernatant was used for measurement of 2’3’-cGAMP. The procedure include a reaction mixture including: 10 mM Tris-HCl, 25 mM KC1, 1 mM DTT , and 3 pg ChimeralO. DNAsealert tube mixed with 5 ml total buffer master mix. Further, 10 pl of cell lysate (described above) was incubated with indicated conditions for 1 hour at 37 °C. ChimeralO activity was measured by monitoring changes in relative fluorescence units (RFU) at the end of the reaction. ChimeralO degrades a fluorescent DNA probe in this reaction in response to 2’3’-cGAMP. Again, as described in Figure 3, ChimeralO displays higher activity, reflecting a higher 2’3’-cGAMP concentration, in lysate derived from WT CdnB expressed during phage infection, as compared to a catalytically dead strain or an empty vector. (Applicant specifically incorporates by reference 63 / 447,555 filed February 22, 2023, with respect to the production, and methods of using chimeric biosensor peptides configured to detect and quantifying 2’3’-Cyclic-GMP-AMP (2’3’ cGAMP)).

[0029] DETAILED DESCRIPTION OF THE INVENTION

[0030] The following detailed description is provided to aid those skilled in the art in practicing the various embodiments of the present disclosure, including all the methods, uses, compositions, etc., described herein. Even so, the following detailed description should not be construed to unduly limit the present disclosure, as modifications and variations in the embodiments herein discussed may be made by those of ordinary skill in the art without departing from the spirit or scope of the present discoveries. In one embodiment, the invention includes a wild-type or modified polypeptide that catalyzes synthesis of 2’3’-Cyclic-GMP-AMP (2’3’-cGAMP), wherein said modified polypeptide comprises an amino acid sequence having at least 70% identity to any one of the amino acid sequences according to SEQ ID NOs. 1-6, or a biologically active fragment thereof. The modified polypeptide can catalyze production of nucleotides in the absence of a ligand, such as doublestranded DNA, and preferably double-stranded DNA is located in the cytoplasm of a cell. In this manner,

[0031] In certain embodiments, 2’3’-cGAMP can be synthesized, for example in vitro, or preferably in a host cell. In this latter embodiment, the 2’3’-cGAMP can be synthesized independent of the action of cyclic GMP-AMP synthase (cGAS), and can further be secreted from the host cell and delivered to a cell of a subject, such as a human or animal, and act as an agonist of the Stimulator of Interferon Genes (STING) receptor. In this manner, activation of STING in a subject occurs independent of cGAS, and without the presence or activity of cGAS.

[0032] In one embodiment, the invention includes a wild-type or modified polypeptide that catalyzes synthesis of 2’3’-cGAMP according to SEQ ID NO. 1-6, or a fragment thereof, wherein the polypeptide further comprising a heterologous polypeptide. In this embodiment, the heterologous polypeptide of the invention is selected from the group consisting of: a signal peptide, a peptide tag, a dimerization domain, an oligomerization domain, an antibody, or an antibody fragment, such as an Fc domain. In still further embodiments, the peptide tag of the invention is a thioredoxra. Maltose-binding protein (MBP), SUMO2. Ghrtathione-S-Transferase (GST), calmodulin binding protein (CBP), protein C tag. Myc tag. HaloTag, HA tag, Flag tag, His tag, biotin tag, V5 tag, or OmpA signal sequence tag.

[0033] In still further embodiments, the invention includes a nucleic acid molecule, and preferably an isolated nucleotide sequence, encoding the polypeptide wild-type or modified polypeptide that catalyzes synthesis of 2’3’-cGAMP according to SEQ ID NO. 1-6, or a fragment thereof. In an alternative embodiment, the invention includes a nucleic acid molecule, and preferably an isolated nucleotide sequence, encoding the polypeptide wild-type or modified polypeptide that catalyzes synthesis of 2’3’-cGAMP according to SEQ ID NO. 1-6, or a fragment thereof, that is operably linked to a promoter forming an expression vector that can be used to transform a host cell, such as bacterial cell or a eukaryotic cell, and preferably a probiotic enteric bacterial cell. In additional embodiments, the host cell appropriate culture medium to, thereby, produce the polypeptide of the invention and / or 2’3’-cGAMP, which can further be isolated from the medium or host cell.

[0034] In still further embodiments, the invention includes a wild-type or modified polypeptide that catalyzes synthesis of 2’3’- 2’3’-cGAMP according to SEQ ID NO. 1-6, or a fragment thereof, and a pharmaceutically acceptable carrier, which can be selected from the group consisting of excipients, and / or diluents. In alternative embodiments, the invention includes a pharmaceutical composition comprising the 2’3’-cGAMP isolated from a host cell, and a pharmaceutically acceptable carrier.

[0035] Additional embodiments may include methods of treating a disease or condition, and preferably a disease or condition that is treatable through the administration of a STING agonist, the method comprising, administering a therapeutically effective amount of the pharmaceutical composition of the invention to a subject in need thereof, wherein the 2’3’-cGAMP activates the STING receptor in the subject.

[0036] Additional embodiments may include methods of treating a disease or condition, and preferably a disease or condition that is treatable through the administration of a STING agonist, the method comprising, administering a therapeutically effective amount of the pharmaceutical composition of the invention to a subject in need thereof, wherein the 2’3’-cGAMP activates the STING receptor in the subject.

[0037] In still further embodiments, the invention includes a pharmaceutical composition comprising a host cell, and preferably a bacterial host cell, expressing a wild-type or modified CD- NTase polypeptide that catalyzes synthesis of 2’3’-cGAMP, or a fragment thereof, and a pharmaceutically acceptable carrier, which can be selected from the group consisting of excipients, and / or diluents. In still further embodiments, the invention includes a pharmaceutical composition comprising a host cell expressing a wild-type or modified polypeptide that catalyzes synthesis of 2’3’-cGAMP according to SEQ ID NO. 1-6, or a fragment thereof, and a pharmaceutically acceptable carrier, which can be selected from the group consisting of excipients, and / or diluents.

[0038] Additional embodiments may include methods of treating a disease or condition, and preferably a disease or condition that is treatable through the administration of a STING agonist, the method comprising, administering a therapeutically effective amount of the pharmaceutical composition of the invention to a subject in need thereof, wherein the 2’3’-cGAMP activates the STING receptor in the subject. Additional embodiment include a non-human animal model, such as a rodent, engineered to express a wild-type or modified polypeptide that catalyzes synthesis of 2’3’-cGAMP according to SEQ ID NO. 1-6, or a fragment thereof. In certain embodiments, the polypeptide is overexpressed in the non-human animal model, which can further include a knock-in or a transgenic animal. In a preferred embodiment, the expression of cGAS has been disrupted or knocked-out.

[0039] Further embodiment include a host cell, and preferably a bacterial cell or a eukaryotic cell, and more preferably a probiotic bacterial cell, which is genetically modified to express a nucleotide sequence encoding heterologous CD-NTase polypeptide that catalyzes biosynthesis of 2’3’- cGAMP, or a biologically active fragment thereof. Further embodiment include a host cell, and preferably a bacterial cell or a eukaryotic cell, and more preferably a probiotic bacterial cell, which is genetically modified to express a nucleotide sequence encoding heterologous polypeptide that catalyzes biosynthesis of 2’3’-cGAMP, wherein said polypeptide comprises an amino acid sequence having at least 70% identity to any one of the amino acid sequences according to SEQ ID NOs. 1-6, or a biologically active fragment thereof.

[0040] Additional embodiment of the invention include method of synthesizing 2’3’-cGAMP comprising the step of contacting one or more CD-NTase polypeptides of the invention that catalyzes biosynthesis of 2’3’-cGAMP, or a biologically active fragment thereof, with the 2’3’- cGAMP nucleotide substrates adenosine triphosphate (ATP), and guanosine-5'-triphosphate (GTP). Synthesis of 2’3’-cGAMP can occur in vitro, in vivo, or ex vitro as described herein.

[0041] Additional embodiments of the invention are directed to isolated nucleic acid molecules that encode a wild-type, or modified polypeptide that catalyzes production of nucleotide-based second messengers, and preferably 2'3'-cGAMP, wherein said polypeptide comprises an amino acid sequence having at least 70% identity to any one of the amino acid sequences for the nucleotidyltransferase proteins (CD-NTase) listed in Table 1 (SEQ ID NO. 1), or derived from the bacterial strains identified in Table 1. As used herein, the term nucleic acid molecule” is intended to include DNA molecules (z.e., cDNA or genomic DNA) and RNA molecules (i.e., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. An “isolated” nucleic acid molecule is one which is separated from other nucleic acid molecules winch are present in the natural source of the nucleic acid. Preferably, an “isolated” nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5 and 3’ ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule that encodes a modified CD- NTase polypeptide, or biologically active portions thereof, can contain less than about 5 kb, 4kb, 3 kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an “isolated” nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized.

[0042] A nucleic acid molecule that encodes a modified CD-NTase polypeptide, and preferably a CD-NTase polypeptide according to SEQ ID NOs. 1-6, or biologically active portions thereof, encompassed by the present invention, can include a nucleotide sequence encoding the same which is at least about 50%, preferably at least about 60%, more preferably at least about 70%, yet more preferably at least about 80%, still more preferably at least about 90%, and most preferably at least about 95% or more (e.g., about 98%) homologous to a sequence encoding a CD-NTase polypeptide according to SEQ ID NOs. 1-6. For example, a modified CD-NTase polypeptide cDNA can be isolated from a bacterium using all or portion of the nucleotide sequence encoding a CD-NTase polypeptide according to SEQ ID NOs. 1-6, or fragment thereof.

[0043] Portions of proteins encoded by the modified CD-NTase nucleic acid molecule encompassed by the present invention are preferably biologically active portions of the modified CD-NTase polypeptide, and preferably a CD-NTase polypeptide according to SEQ ID NOs. 1-6, or fragment thereof. As used herein, the term “biologically active portion” of the modified CD- NTase polypeptide is intended to include a portion, e.g., a domain / motif of the modified CD-NTase polypeptide that has one or more of the biological activities of the full-length modified CD-NTase polypeptide, respectively. The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences shown in Table 1, or fragments thereof due to degeneracy of the genetic code and thus encode the same modified CD-NTase polypeptide, or fragment thereof. In another embodiment an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in Table 1, or fragments thereof or a protein having an amino acid sequence which is at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homologous to an amino acid sequence shown in Table 1, or fragments thereof, or differs by at least 1, 2, 3, 5 or 10 amino acids but not more than 30, 20, 15 amino acids from an amino acid sequence shown in Table 1. In another embodiment a nucleic acid encoding a modified CD-NTase polypeptide consists of nucleic acid sequence encoding a portion of a full-length modified CD-NTase polypeptide of interest that is less than 195, 190, 185, 180, 175, 170, 165, 160, 155, 150, 145, 140, 135, 130, 125, 120 115, 1 10. 105, 100, 95, 90. 85, 80, 75, or 70 amino acids in length .

[0044] It will he appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the modified CD-NTase polypeptides may exist within a population (e.g., a bacterial population). Such genetic polymorphism in the modified CD- NTase genes, for example encoding the amino acid sequences according to SEQ ID NOs. 1-6, may exist among individuals within a population due to natural allelic variation. As used herein, the terms “gene” and recombinant gene” refer to nucleic acid molecules comprising an open reading frame encoding a modified CD-NTase protein. Such natural allelic variations can typically result in 1 -5% variance in the nucleotide sequence of the modified CD-NTase gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in the modified CD-NTase polypeptide that are the result of natural allelic variation and that do not alter the functional activity of the modified CD-NTase polypeptide are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the modified CD-NTase cDNAs encompassed by the present invention can be isolated based on their homology to the modified CD-NTase nucleic acid sequences disclosed herein using the bacterium cDNA, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions (as described herein).

[0045] In addition to naturally-occurring allelic variants of the modified CD-NTase polypeptide sequence that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences shown in Table 1, or fragments thereof, thereby leading to changes in the amino acid sequence of the encoded modified CD-NTase polypeptide, without altering the functional ability of the modified CD-NTase polypeptide. For example, nucleotide substitutions leading to amino acid substitutions of “non-essential” amino acid residues can be made in the sequence shown in Table 1, or fragments thereof. A “non- essential” amino acid residue is a residue that can be altered from the sequence of the modified CD-NTase polypeptide (e.g., the sequence shown in Table 1, or fragments thereof) without significantly altering the activity of the modified CD-NTase polypeptide, whereas an “essential” amino acid residue is required for the modified CD-NTase polypeptide activity. Other amino acid residues, however, (e.g., those that are not conserved or only semi-conserved across bacterial species) may not be essential for activity and thus are likely to be amenable to alteration without altering the modified CD-NTase polypeptide activity.

[0046] Accordingly, another aspect encompassed by the present invention pertains to nucleic acid molecules encoding modified CD-NTase polypeptides that contain changes in amino acid residues that are not essential for the modified CD-NTase polypeptide activity. Such modified CD-NTase polypeptides differ in amino acid sequence from an amino acid sequence shown in Table 1, or fragments thereof, yet retain at least one of the modified CD- NTase polypeptide activities described herein. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein lacks one or more modified CD-NTase polypeptide domains.

[0047] An isolated nucleic acid molecule encoding a modified CD-NTase polypeptide homologous to the proteins show in Table 1, or fragments thereof, can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequences shown in Table 1, or fragments thereof, or a homologous nucleotide sequence such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into a nucleotide sequence shown in Table 1, or fragments thereof, or to homologous nucleotide sequence by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain . Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine isoleucine, proline, phenylalanine methionine, tryptophan) branched side chains (e.g., threonine, valine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in the modified CD-NTase polypeptide is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a modified CD-NTase polypeptide coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for the modified CD-NTase polypeptide activity described herein to identify mutants that retain the modified CD-NTase polypeptide activity. Following mutagenesis of a nucleotide sequence shown in Table 1, or fragments thereof, the encoded protein can be expressed recombinantly (as described herein) and the activity of the protein can he determined using, for example, assays described herein.

[0048] Another aspect of the invention pertains to the use of vectors preferably expression vectors, containing a nucleic acid encoding a modified CD-NTase polypeptide (or a portion thereof), and preferably encoding a sequence according to SEQ ID NOs. 1-6, or fragment thereof. As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid” , which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, where in additional DMA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non- episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “expression vectors”. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, “plasmid” and “vector” can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions. In one embodiment, adenoviral vectors comprising a modified CD- NTase nucleic acid molecule are used.

[0049] The recombinant expression vectors encompassed by the present invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, such as a promoter, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in vitro transcription / translation system or in a host cell when the vector is introduced into the host cell). The term “‘regulatory sequence” is intended to include promoters, enhancers and other expression control dements (e.g.. polyadenylation signals).

[0050] Another aspect encompassed by the present invention pertains to host cells into which a recombinant expression vector or nucleic acid encompassed by the present invention has been introduced. The terms “host cell” and “recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the disclosure as used herein.

[0051] A host cell can be any prokaryotic or eukaryotic cell. For example, the modified CD-NTase polypeptide can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells. Other suitable host cells are known to those skilled in the art. Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms transformation” and “transfection” are intended to refer to a variety of art- recognized techniques for introducing foreign nucleic acid (e.g. DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals.

[0052] A cell culture includes host cells, media and other byproducts. Suitable media for cell culture are well-known in the art. A modified CD-NTase polypeptide or fragment thereof may be secreted and isolated from a mixture of cells and medium containing the polypeptide. Alternatively, a modified CD-NTase polypeptide or fragment thereof may be retained in the cytoplasm and the cells harvested, lysed and the protein or molecular complex isolated. A modified CD-NTase polypeptide or fragment thereof, or synthesis product including preferably 2’3’- cGAMP may be isolated from cell culture medium, host cells, or both using techniques known in the art for purifying proteins or chemical compounds, including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for particular epitopes of the modified CD-NTase polypeptide, or a fragment thereof, or 2’3’-cGAMP molecule. In some embodiments, the modified CD-NTase polypeptide, or biologically active fragment thereof, and may be fused to a heterologous polypeptide. In certain embodiments, the fused polypeptide has greater half-life and / or cell permeability than the corresponding unfused modified CD-NTase polypeptide, or biologically active fragment thereof. For example, the modified CD-NTase polypeptide may be fused to a cell permeable peptide to facilitate the delivery of the modified CD-NTase polypeptide into the intact cells.

[0053] In another embodiment, protein production may be achieved using in vitro translation systems. In vitro translation systems are, generally, a translation system which is a cell-free extract containing at least the minimum elements necessary for translation of an RNA molecule into a protein. An in vitro translation system typically comprises at least ribosomes, tRNAs, initiator methionyl-tRNAMet, proteins or complexes involved in translation, e.g., eIF2, eIF3, the capbinding (CB) complex, comprising the cap-binding protein (CBP) and eukaryotic initiation factor 4F (eIF4F). A variety of in vitro translation systems are well-known in the art and include commercially available kits. Examples of in vitro translation systems include eukaryotic lysates, such as rabbit reticulocyte lysates, rabbit oocyte lysates, human cell lysates, insect cell lysates and wheat ger extracts.

[0054] In certain embodiments, the modified CD-NTase polypeptide, or fragment thereof may be synthesized chemically, ribosomally in a cell free system, or ribosomally within a cell. Chemical synthesis may be carried out using a variety of art recognized methods, including stepwise solid phase synthesis, semi-synthesis through the conformationally-assisted re-ligation of peptide fragments, enzymatic ligation of cloned or synthetic peptide segments, and chemical ligation. Native chemical ligation employs a chemo-selective reaction of two unprotected peptide segments to produce a transient thioester-linked intermediate. The transient thioester-linked intermediate then spontaneously undergoes a rearrangement to provide the full length ligation product having a native peptide bond at the ligation site. Full length ligation products are chemically identical to proteins produced by cell free synthesis. Full length ligation products may be refolded and / or oxidized, as allowed, to form native disulfide-containing protein molecules For stable transfection of cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as antibiotics. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding the modified CD-NTase polypeptide or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

[0055] A host cell encompassed by the present invention, such as a prokaryotic or eukaryotic host cell in culture can be used to produce (i.e. , express) the CD-NTase polypeptide, and / or 2’3’- cGAMP. Accordingly, the invention further provides methods for producing the modified CD- NTase polypeptide and / or 2’3’-cGAMP using the host cells of the invention. In one embodiment, the method composes culturing the host cell of invention (into which a recombinant expression vector encoding the modified CD-NTase polypeptide has been introduced) in a suitable medium until the CD-NTase polypeptide and / or 2’3’-cGAMP is produced. In another embodiment, the method further comprises isolating the CD-NTase polypeptide and / or 2’3’-cGAMP from the medium or the host cell.

[0056] The host cells of the invention can also be used to produce human or non-human transgenic animals and / or cells that, for example, overexpress the modified CD-NTase polypeptide or oversecrete the modified CD-NTase polypeptide. The non-human transgenic animals can be used in screening assays designed to identify agents or compounds, e.g., drugs, pharmaceuticals, etc. , winch are capable of ameliorating detrimental symptoms of selected disorders such as cancer, as well as evaluate the use of and / or 2’3’-cGAMP as a therapeutic compound, for example secreted through a probiotic bacteria administered to a subject that is not transgenic or otherwise modified. As used herein, a transgenic animal” is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops, and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal.

[0057] The present invention also provides soluble, purified and / or isolated forms of wild-type or modified CD-NTase polypeptides that catalyzes production of the second messenger 2’3’- cGAMP, wherein said polypeptide comprises an amino acid sequence having at least 70% identity to any one of CD-NTase amino acid sequences listed in Table 1 and further comprises a nucleotidyltransferase protein. An amino acid sequence of any modified CD-NTase polypeptide described herein can also be at least 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 99.5% identical to a CD-NTase amino acid sequence of any one of CD-NTase amino acid sequences listed in Table 1, or a fragment thereof. In another aspect, the present invention contemplates a composition comprising an isolated wild-type or modified CD-NTase polypeptide described herein and less than about 25%, or alternatively 15%, or alternatively 5%, contaminating biological macromolecules or polypeptides.

[0058] The present invention further provides compositions related to producing, detecting, or characterizing a modified CD-NTase polypeptide, or fragment thereof, such as nucleic acids, vectors, host cells and the like. Such compositions may serve as compounds that modulate a modified CD-NTase polypeptide’s expression and / or activity, such as antisense nucleic acids.

[0059] In certain embodiments, a modified CD-NTase polypeptide of the invention may be a fusion protein containing a domain which increases its solubility and bioavailability and / or facilitates its purification, identification, detection, and / or structural characterization. In some embodiments, it may be useful to express a modified CD-NTase polypeptide in which the fusion partner enhances fusion protein stability in blood plasma and / or enhances systemic bioavailability. Exemplary domains include for example, glutathione S- transferase (GST), protein A, protein G, calmodulin-binding peptide, thioredoxin, maltose binding protein, HA, myc, poly arginine, poly His, poly His-Asp or FLAG fusion proteins and tags. Additional exemplary' domains include domains that alter protein localization in vivo, such as signal peptides, type 2 or 1 secretion systemtargeting peptides, transcytosis domains, nuclear localization signals, etc. In various embodiments, a modified CD-NTase polypeptide of the invention may comprise one or more heterologous fusions.

[0060] Polypeptides may contain multiple copies of the same fusion domain or may contain fusions to two or more different domains. The fusions may occur at the N-terminus of the polypeptide, at the C-terminus of the polypeptide, or at both the N- and C-terminus of the polypeptide. It is also within the scope of the invention to include linker sequences between a polypeptide of the invention and the fusion domain in order to facilitate construction of the fusion protein or to optimize protein expression or structural constraints of the fusion protein. In another embodiment, the polypeptide may be constructed so as to contain protease cleavage sues between the fusion polypeptide and polypeptide of the invention in order to remove the tag after protein expression or thereafter. Examples of suitable endoproteases include, for example, Factor Xa and TEV proteases, in some embodiments, the modified CD-NTase polypeptides, or fragments thereof, are fused to an antibody (e.g., IgG 1, IgG2, IgG3, IgG4) fragment (e.g., Fc polypeptides).

[0061] In still another embodiment, a modified CD-NTase polypeptide may be labeled with a fluorescent label to facilitate their detection, purification, or structural characterization. In an exemplary embodiment, a modified CD-NTase polypeptide of the invention may be fused to a heterologous polypeptide sequence which produces a detectable fluorescent signal, including, for example, green fluorescent protein (GFP), enhanced green fluorescent protein (EGFP), GFPmut2, GFPuv4, enhanced yellow fluorescent protein (EYFP), enhanced cyan fluorescent protein (E- CFP), enhanced blue fluorescent protein (EBFP), citrine and red fluorescent protein from discosoma fdsRED).

[0062] In preferred embodiments, the modified CD-NTase polypeptide or portion thereof comprises an amino acid sequence which is sufficiently homologous to an amino acid sequence shown in Table 1 or fragment thereof catalyzes production of 2’3’ cGAMP. The portion of the protein is preferably a biologically active portion as described herein. In another preferred embodiment, the modified CD-NTase polypeptides has an amino acid sequence shown in Table 1, or fragments thereof, or an amino acid sequence which is at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in Table 1, or fragment thereof.

[0063] Biologically active portions of a modified CD-NTase polypeptide include peptides comprising amino acid sequences derived from the amino acid sequence of the modified CD- NTase protein, or the amino acid sequence of a protein homologous to the modified CD-NTase protein which include fewer amino acids than the full-length modified CD- NTase protein or the full-length polypeptide which is homologous to the modified CD- NTase protein, and exhibit at least one activity of the modified CD-NTase protein, namely synthesis of 2’ 3 ’-cGAMP. Typically, biologically active portions (peptides, e.g., peptides which are, for example, 50, 55 60, 65 70, 75, 80, 85, 90 95, 100 or more amino acids in length) comprise a domain or motif (e.g., the full-length protein minus the signal peptide). In a preferred embodiment, the biologically active portion of the protein which includes one or more the domains / motifs described herein catalyzes production of 2’3’-cGAMP. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the activities described herein. Preferably, the biologically active portions of the modified CD-NTase protein include one or more selected domains / motifs or portions thereof having biological activity. In one embodiment, a modified CD-NTase polypeptide fragment of interest consists of a portion of a full-length modified CD-NTase polypeptide that is less than 240, 230, 220, 210, 200, 195. 190, 185, 180, 175, 170, 165, 160, 155, 150. 145, 140, 135, 130, 125, 120, 115, 1 10, 105, 100, 95, 90, 85, 80, 75, or 70 amino acids in length.

[0064] The modified CD-NTase polypeptides of the precent invention can be produced by recombinant DNA techniques. For example, a nucleic acid molecule encoding the protein is cloned into an expression vector (as described above), the expression vector is introduced into a host cell (as described above) and the modified CD-NTase polypeptide is expressed in the host cell, which can produce 2’3’-cGAMP independent of the cGAS pathway, and without the present of a ligand, such as DNA. The modified CD-NTase polypeptide and / or synthesized 2’3’-cGAMP can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. In alternative embodiments, the host cell can include, for example a transformed, or genetically modified cell, such as a bacteria that heterologously expresses CD-NTase polypeptide. This host cell can be administered to a subject, such as an animal, and more preferably a human and colonize the subject where the CD-NTase polypeptide synthesizes 2’3’-cGAMP which can be secreted by the host cell and thereby administered to the subject. In a preferred embodiment, the host cell is a probiotic bacterium, and preferably a human enteric probiotic bacterium.

[0065] Alternative to recombinant expression, a modified CD-NTase protein, polypeptide, or peptide can be synthesized chemically using standard peptide synthesis techniques. Moreover, modified CD-NTase protein can be isolated from cells (e.g., engineered cells that harboring modified CD-NTase), for example using an anti-CD-NTase antibody. The invention also provides modified CD-NTase chimeric or fusion proteins. As used herein, a modified CD-NTase ‘“chimeric protein” or “fusion protein” comprises a modified CD-NTase polypeptide operatively linked to a non-CD-NTase polypeptide.

[0066] A “modified CD-NTase polypeptide” refers to a polypeptide having an amino acid sequence having at least 70% identity to CD-NTase shown in Table 1, whereas a “non-CD-MTase polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the modified CD-NTase protein, e.g., a protein winch is different from the modified CD-NTase protein and which is derived from the same or a different organism. Within the fusion protein, the term “operatively linked” is intended to indicate that the modified CD-NTase polypeptide and the non-CD-NTase polypeptide are fused in-frame to each other. The non-CD-NTase polypeptide can be fused to the N-terminus or C- terminus of the modified CD-NTase polypeptide. For example, in one embodiment the fusion protein is a modified CD-NTase-GST and / or modified CD-NTase-Fc fusion protein in which the modified CD-NTase sequences, respectively, are fused to the -terminus of the GST or Fc sequences. Such fusion proteins can be made using the modified CD-NTase polypeptides. Such fusion proteins can also facilitate the purification, expression and / or bioavailability of recombinant modified CD-NTase polypeptides. In another embodiment, the fusion protein is a modified CD-NTase protein containing a heterologous signal sequence at its C-terminus. In certain host cells (e.g., mammalian or bacterial host cells), expression and / or secretion of the modified CD-NTase polypeptides and the resulting synthesized 2’3’-cGAMP can be increased through use of a heterologous sequences.

[0067] The present invention also pertains to homologues of the modified CD-NTase proteins. Homologues of the modified CD-NTase protein can be generated by mutagenesis, e.g., discrete point mutation or truncation of the modified CD-NTase protein, respectively. As used herein, the term “homologue” refers to a variant form of the modified CD-NTase protein. In one embodiment, treatment of a subject with a homologue having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the modified CD- NTase protein.

[0068] In an alternative embodiment, homologues of the modified CD-NTase protein can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the modified CD-NTase protein . In one embodiment, a variegated library of the modified CD-NTase variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of the modified CD-NTase variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential modified CD- NTase sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of the modified CD-NTase sequences therein. There are a variety of methods which can be used to produce libraries of potential modified CD-NTase homologues from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in art automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired se t of potential modified CD-NTase sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang, S.A. (1983) Tetrahedron 39:3; Itakura et al. (1984) Amu. Rev. Biochem. 53:323; Itakura et al. (1984} Science 198: 1056; Ike et al. (1983) Nucleic Acid Res. 11 :477

[0069] In addition, libraries of fragments of the modified CD-NTase protein coding can be used to generate a population of the modified CD-NTase fragments for screening and subsequent selection of homologues of a modified CD-NTase protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a modified CD-NTase coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense / antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with SI nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N- terminal, C-terminal and internal fragments of various sizes of the modified CD-NTase protein.

[0070] The modified CD-NTase nucleic acid and polypeptide molecules described herein may be used to produce 2’3’-cGAMP. For example, the modified CD-NTase nucleic acid or polypeptide molecules may be delivered into a cell, or an organism cultured at an optimal condition so that the modified CD-NTase nucleic acid or polypeptide molecules catalyze 2’3’-cGAMP synthesis. The delivery method is known in the art and also described herein. For example, the modified CD- NTase nucleic acid or polypeptide molecules may be delivered using chemical vehicles like liposomes or through viral delivery. In other embodiments, the modified CD-NTase nucleic acid or polypeptide molecules may be contacted with nucleotide substrates in a cell-fee condition where buffers, ions, and / or ligands required for the catalytic activity of the modified CD-NTase are supplied.

[0071] 2’3’-cGAMP synthesis by the CD-NTases of the invention can be modulated further in addition to expressing the CD-NTases. For example, the nucleotide substrates may be modified, or unnatural nucleotides as described in the definitions, so that the 2’3’-cGAMP synthesized may include modified or unnatural nucleotides. Methods for identifying, purifying, and / or characterizing the produced 2’3’-cGAMP are known in the art. The CD-NTases themselves and / or 2’3’-cGAMP produced using the modified CD-NTase nucleic acid and polypeptide molecules described herein, can be used as therapeutics, preferably as part of pharmaceutical compositions as described herein, for example through probiotic delivery systems.

[0072] The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection local administration (see ITS. Pat. No. 5,328,470) or by stereotactic injection (see e.g., Chen et at (1994) Proc. Natl. Acad. Set USA 91 :3054 3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells winch produce the gene delivery system.

[0073] Unless otherwise defined, all terms of art, notations and other scientific terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this invention pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and / or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art. The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodology by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual 3rd. edition (2001) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. and Current Protocols in Molecular Biology (Ausbel et al., eds., John Wiley & Sons, Inc. 2001. As appropriate, procedures involving the use of commercially available kits and reagents are generally carried out in accordance with manufacturer defined protocols and / or parameters unless otherwise noted.

[0074] The term “STING pathway” or “cGAS-STING pathway” refers to a STING - regulated innate immune pathway, which mediates cytosolic DMA-induced signaling events. Cytosolic DNA binds to and activates cGAS, which catalyzes the synthesis of 2’3’ - cGAMP from ATP and GTP. 2’ 3 ’-cGAMP binds to the ER adaptor STING, which traffics to the ER-Golgi intermediate compartment (ERG1C) and the Golgi apparatus. STING then activates IKK and TBK1. TBK1 phosphorylates STING, which in turn recruits IRF3 for phosphorylation by TBK1. Phosphorylated IRF3 dimerizes and then enters the nucleus, where it functions with NF-kB to turn on the expression of type I interferons and other immunomodulatory molecules. The cGAS-STTNG pathway not only mediates protective immune defense against infection by a large variety of DNA- containing pathogens but also detects tumor-derived DNA and generates intrinsic antitumor immunity. However, aberrant activation of the CGAS-STING pathway by self-DNA can also lead to autoimmune and inflammatory' disease.

[0075] The term “cGAS” or “Cyclic GMP-AMP Synthase”, refers to nucleotidyltransferases that catalyzes the formation of cyclic GMP-AMP (cGAMP) from ATP and GTP

[0076] The term “peptide” as used herein, refers to any of various amides that are derived from two or more amino acids by combination of the amino group of one acid with the carboxyl group of another and are usually obtained by partial hydrolysis of proteins. In general, a peptide comprises amino acids having an order of magnitude with the tens. As noted above, the terms protein and peptide also include protein fragments, epitopes, catalytic sites, signaling sites, localization sites and the like. A peptide or protein may further be a fusion or chimera peptide, which a used herein means a peptide having at least a first and second domain or moiety. As described herein, in certain embodiment various peptides, including chimeric peptides or oligonucleotides, such as RNA molecules may be co-expressed. In some embodiments the elements may be co-expressed from a single expression vector having one or more expression cassettes, or from separate expression vectors having one or more expression cassettes. Such expression may also be the result of transient or stable transformation of a cell. As used herein, a “functional” polypeptide or “functional fragment” is one that substantially retains at least one biological activity normally associated with that polypeptide (e.g., nucleosome formation). The terms “polypeptides” and “proteins” are, where applicable, used interchangeably herein. They may be chemically modified, e.g. post-translationally modified. For example, they may be glycosylated or comprise modified amino acid residues. They may also be modified by the addition of a signal sequence to promote their secretion from a cell where the polypeptide does not naturally contain such a sequence. They may be tagged with a tag. They may be tagged with different labels which may assists in identification of the proteins in a molecular complex. Polypeptide s / proteins for use in the Invention may be in a substantially isolated form. It will be understood that the polypeptide / protein may be mixed with earners or diluents which will not interfere with the intended purpose of the polypeptide and still be regarded as substantially isolated.

[0077] Unless otherwise stated, nucleic acid sequences in the text of this specification are given, when read from left to right, in the 5' to 3' direction. Nucleic acid sequences may be provided as DNA or as RNA, as specified; disclosure of one necessarily defines the other, as is known to one of ordinary skill in the art and is understood as included in embodiments where it would be appropriate. Nucleotides may be referred to by their commonly accepted single-letter codes. Unless otherwise indicated, amino acid sequences are written left to right in amino to carboxyl orientation, respectively. Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols as generally understood by those skilled in the relevant art.

[0078] The term “fragment,” as applied to a polynucleotide, can further be understood to mean a nucleotide sequence of reduced length relative to a reference nucleic acid or nucleotide sequence and comprising, consisting essentially of, and / or consisting of a nucleotide sequence of contiguous nucleotides identical or almost identical (e.g., at least 90%, 92%, 95%, 98%, 99% identical) to the 25 reference nucleic acid or nucleotide sequence. Such a nucleic acid fragment according to the invention may be, where appropriate, included in a larger polynucleotide of which it is a constituent. In some embodiments, such fragments can comprise, consist essentially of, and / or consist of oligonucleotides having a length of at least about 8, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 150, 200, or more consecutive nucleotides of a nucleic acid or nucleotide sequence 30 according to the invention. In some embodiments, such fragments can comprise, consist essentially of, and / or consist of oligonucleotides having a length of less than about 8, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 150, or 200 consecutive nucleotides of a nucleic acid or nucleotide sequence according to the invention.

[0079] The term “isolated,” when applied to a nucleic acid or protein, denotes that the nucleic acid or protein is essentially free of other cellular components with which it is associated in the natural state. It is preferably in a homogeneous state although it can be in either a dry or aqueous solution. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein which is the predominant species present in a preparation is substantially purified. In particular, a 10 isolated gene is separated from open reading frames which flank the gene and encode a protein other than the gene of interest. The term “purified” denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Particularly, it means that the nucleic acid or protein is at least 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure.

[0080] An “isolated protein” refers to a protein that is substantially free of other proteins, cellular material, separation medium and culture medium when isolated from cells or produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. An ’’isolated” or ’’purified” protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the antibody, polypeptide, peptide or fusion protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language ’’substantially free of cellular material” includes preparations of a polypeptide or fragment thereof, in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced hi one embodiment, the language “substantially free of cellular material” includes preparations of a modified CD-NTase polypeptide or fragment thereof having less than about 30% (by dry- weight) of non-CD-NTase protein (also referred to herein as a “contaminating protein”), more preferably less than about 20% of non-CD-NTase protein, still more preferably less than about 10% of non-CD-NTase protein, and most preferably less than about 5% non- CD- NTase protein. When antibody polypeptide, peptide or fusion protein or fragment thereof e.g., a biologically active fragment thereof, is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation The term “modified CD-NTase polypeptide” refers to CD-NTase polypeptide that is different from that found in nature, in its native or original cellular or body environment. The term “modification” as used herein refers to all modifications of a protein, DNA, or protein-DNA complex of the invention including cleavage and addition or removal of a group. The “modified CD-NTase polypeptide” of this invention may be, e.g. homolog, derivative, or fragment of native CD-NTase polypeptide having an amino acid sequence listed in Table 1. Preferably, the “modified CD-NTase polypeptide” has one or more following biological activities: a) circular or linear nucleotide-based second messenger synthesis; b) active enzyme conformation; and c) STING or RECON pathway regulation. The term “modified CD-NTase nucleic acid” refers to nucleic acid (e.g., DNA, mRNA) that encodes the modified CD-NTase polypeptide of described herein. As used herein, the term nucleotide-based second messenger’ refers to a second messenger having a relatively small number (e.g., one, two, or three) of nucleotides or derivatives thereof that transduces signals originating from changes in the environment or in intracellular conditions into appropriate cellular responses. It can be circular or linear. In one embodiment, the nucleotide- based second messenger is a cyclic dinucleotide which includes but is not limited to 2’3’=cGAMP. he nucleotide-based second messenger may contain modified or unnatural nucleotides. The modified nucleotides can be naturally occurring modified RNA base analogs (Limbaeh et al. (1994) Nucleic Acids Res 22:2183-2196: Cantara et al. (2011) Nucleic Adds Res 39:0195-0201; Czerwoniec et al. (2009) Nucleic Acids Res 37:D118- D121 ; Grosjean et al. (1998) Modification and Editing of RNA. ASM Press, Washington DC.)

[0081] As used herein, an “agonist” means a substance, having the function of binding / activating to a receptor or to produce a biological response.

[0082] A “marker”, or “tag” as used herein, refers to a molecule that can be used for identification, detection, purification, or isolation. In an embodiment, the marker comprises a small molecule, a peptide, a polypeptide, or a labeled amino acid or nucleotide. In an embodiment, the marker generates a signal for detection, e.g., a radioactive signal, a chemiluminescent signal, a fluorescent signal, or a chromogenic signal. For example, the marker is a dye, a fluorophore, a reporter enzyme (e.g., a photoprotein, luciferase), a fluorescent peptide, or a radionuclide. The generated signal can be detected by a variety of assays known in the art, such as fluorescence microscopy, fluorescence- activated cell sorting, gel electrophoresis, and spectrophotometry. A “subject” is any organism of interest, generally a mammalian subject, and preferably a human subject.

[0083] The term “probiotic” refers to a microorganism, such as bacteria, which may colonize a host. A probiotic may include endosymbiotic bacteria, or naturally occurring flora that may permanently to temporarily colonize an animal, such as a human. Probiotic organisms may also include human gut probiotic strains.

[0084] The term “expression,” as used herein, or “expression” of a coding sequence (for example, a gene or a transgene) refers to the process by which the coded information of a nucleic acid transcriptional unit (including, e.g., genomic DNA or cDNA) is converted into an operational, non- operational, or structural part of a cell, often including the synthesis of a protein. Gene expression can be influenced by external signals; for example, exposure of a cell, tissue, or organism to an agent that increases or decreases gene expression. Expression of a gene can also be regulated anywhere in the pathway from DNA to RNA to protein. Regulation of gene expression occurs, for example, through controls acting on transcription, translation, RNA transport and processing, degradation of intermediary molecules such as mRNA, or through activation, inactivation, compartmentalization, or degradation of specific protein molecules after they have been made, or by combinations thereof. Gene expression can be measured at the RNA level or the protein level by any method known in the art, including, without limitation, Northern blot, RT-PCR, Western blot, or in vitro, in situ, or in vivo protein activity assay(s).

[0085] The term “nucleic acid” or “nucleic acid molecules” include single- and double- stranded forms of DNA; single- stranded forms of RNA; and double-stranded forms of RNA (dsRNA). The term “nucleotide sequence” or “nucleic acid sequence” refers to both the sense and antisense strands of a nucleic acid as either individual single strands or in the duplex.

[0086] The term “gene” or “sequence” refers to a coding region operably joined to appropriate regulatory sequences capable of regulating the expression of the gene product (e.g., a polypeptide or a functional RNA) in some manner. A gene includes untranslated regulatory regions of DNA (e.g., promoters, enhancers, repressors, etc.) preceding (up-stream) and following (down- stream) the coding region (open reading frame, ORF) as well as, where applicable, intervening sequences (i.e., introns) between individual coding regions (i.e., exons).

[0087] A nucleic acid molecule may include either or both naturally occurring and modified nucleotides linked together by naturally occurring and / or non-naturally occurring nucleotide linkages. Nucleic acid molecules may be modified chemically or biochemically, or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, intemucleotide modifications (e.g., uncharged linkages: for example, methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.; charged linkages: for example, phosphorothioates, phosphorodithioates, etc.; pendent moieties: for example, peptides; intercalators: for example, acridine, psoralen, etc.; chelators; alkylators; and modified linkages: for example, alpha anomeric nucleic acids, etc.). The term “nucleic acid molecule” also includes any topological conformation, including single-stranded, double-stranded, partially duplexed, triplexed, hairpinned, circular, and padlocked conformations.

[0088] The term “sequence identity” or “identity,” as used herein in the context of two nucleic acid or polypeptide sequences, refers to the residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window. As used herein, the term “percentage of sequence identity” may refer to the value determined by comparing two optimally aligned sequences (e.g., nucleic acid sequences) over a comparison window, wherein the portion of the sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleotide or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window, and multiplying the result by 100 to yield the percentage of sequence identity. A sequence that is identical at every position in comparison to a reference sequence is said to be 100% identical to the reference sequence, and vice-versa.

[0089] Notably, disclosure of a nucleotide sequence also specifically includes with the disclosure its corresponding RNA and amino acid sequence, and vice versa.

[0090] Polynucleotide sequences may have substantial identity, substantial homology, or substantial complementarity to the selected region of the target gene. As used herein “substantial identity” and “substantial homology” indicate sequences that have sequence identity or homology to each other. Generally, sequences that are substantially identical or substantially homologous will have about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity wherein the percent sequence identity is based on the entire sequence and is determined by GAP alignment using default parameters (GCG, GAP version 10, Accelrys, San Diego, CA). GAP uses the algorithm of Needleman and Wunsch ((1970) J Mol Biol 48:443-453) to find the alignment of two complete sequences that maximizes the number of matches and minimizes the number of sequence gaps. Sequences which have 100% identity are identical. “Substantial complementarity” refers to sequences that are complementary to each other, and are able to base pair with each other. In describing complementary sequences, if all the nucleotides in the first sequence will base pair to the second sequence, these sequences are fully complementary.

[0091] Methods for aligning sequences for comparison are well-known in the art. Various programs and alignment algorithms are described in, for example: Smith and Waterman (1981) Adv. Appl. Math. 2:482; Needleman and Wunsch (1970) J. Mol. Biol. 48:443; Pearson and Lipman (1988) Proc. Natl. Acad. Sci. U.S.A. 85:2444; Higgins and Sharp (1988) Gene 73:237-44; Higgins and Sharp (1989) CABIOS 5:151-3; Corpet et al. (1988) Nucleic Acids Res. 16: 10881- 90; Huang et al. (1992) Comp. Appl. Biosci. 8: 155-65; Pearson et al. (1994) Methods Mol. Biol. 24:307-31; Tatiana et al. (1999) FEMS Microbiol. Lett. 174:247-50. A detailed consideration of sequence alignment methods and homology calculations can be found in, e.g., Altschul et al. (1990) J. Mol. Biol. 215:403-10. The National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST™; Altschul et al. (1990)) is available from several sources, including the National Center for Biotechnology Information (Bethesda, Md.), and on the internet, for use in connection with several sequence analysis programs. A description of how to determine sequence identity using this program is available on the internet under the “help” section for BLAST™. For comparisons of nucleic acid sequences, the “Blast 2 sequences” function of the BLAST™ (Blastn) program may be employed using the default BLOSUM62 matrix set to default parameters. Nucleic acid sequences with even greater similarity to the reference sequences will show increasing percentage identity when assessed by this method.

[0092] As used herein, the term “homologous” with regard to a contiguous nucleic acid sequence, refers to contiguous nucleotide sequences that hybridize under appropriate conditions to the reference nucleic acid sequence. For example, homologous sequences may have from about 70%- 100, or more generally 80% to 100% sequence identity, such as about 81%; about 82%; about 83%; about 84%; about 85%; about 86%; about 87%; about 88%; about 89%; about 90%; about 91%; about 92%; about 93%; about 94% about 95%; about 96%; about 97%; about 98%; about 98.5%; about 99%; about 99.5%; and about 100%. The property of substantial homology is closely related to specific hybridization. For example, a nucleic acid molecule is specifically hybridizable when there is a sufficient degree of complementarity to avoid non-specific binding of the nucleic acid to non-target sequences under conditions where specific binding is desired, for example, under stringent hybridization conditions.

[0093] Homologs, variants and alleles of the target molecules or proteins of the invention can be identified by conventional techniques. As used herein, a homolog or variant to a polypeptide is a polypeptide from a source that has a high degree of structural similarity to the identified polypeptide. The terms “derivatives”, “analogs” or “variants” as used herein include, but are not limited, to molecules comprising regions that are substantially homologous to the modified CD- NTase polypeptide, in various embodiments, by at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99% identity over an amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to a sequence encoding the component protein under stringent, moderately stringent, or non-stringent conditions. It means a protein which is the outcome of a modification of the naturally occurring protein, by amino acid substitution, deletions and additions, respectively, which derivatives still exhibit the biological function of the naturally occurring protein although not necessarily to the same degree. The biological function of such proteins can e.g., be examined by suitable available in vitro assays as provided in the invention.

[0094] The term, “operably linked,” when used in reference to a regulatory sequence and a coding sequence, means that the regulatory sequence affects the expression of the linked coding sequence. “Regulatory sequences,” or “control elements,” refer to nucleotide sequences that influence the timing and level / amount of transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters; translation leader sequences; introns; enhancers; stem-loop structures; repressor binding sequences; termination sequences; polyadenylation recognition sequences; etc. Particular regulatory sequences may be located upstream and / or downstream of a coding sequence operably linked thereto. Also, particular regulatory sequences operably linked to a coding sequence may be located on the associated complementary strand of a double-stranded nucleic acid molecule.

[0095] As used herein, the term “promoter” refers to a region of DNA that may be upstream from the start of transcription, and that may be involved in recognition and binding of RNA polymerase and other proteins to initiate transcription. A promoter may be operably linked to a coding sequence for expression in a cell, or a promoter may be operably linked to a nucleotide sequence encoding a signal sequence which may be operably linked to a coding sequence for expression in a cell.

[0096] As used herein, the term “transformation” or “genetically modified” refers to the transfer of one or more nucleic acid molecule(s) into a cell. A microorganism is “transformed” or “genetically modified” by a nucleic acid molecule transduced into the bacteria when the nucleic acid molecule becomes stably replicated by the bacteria. As used herein, the term “transformation” or “genetically modified” encompasses all techniques by which a nucleic acid molecule can be introduced into such a bacteria.

[0097] As used herein, the term “host cell” is intended to refer to a cell into which a nucleic- acid encompassed by the present invention, such as a recombinant expression vector encompassed by the present invention, has been introduced. The terms “host cell” and “recombinant host cell” are used interchangeably herein . It should be understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not. in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

[0098] The term “vector” refers to some means by which DNA, RNA, a protein, or polypeptide can be introduced into a host. The polynucleotides, protein, and polypeptide which are to be introduced into a host can be therapeutic or prophylactic in nature; can encode or be an antigen; can be regulatory in nature, etc. There are several types of vectors including virus, plasmid, bacteriophages, cosmids, and bacteria.

[0099] An “expression vector” is nucleic acid capable of replicating in a selected host cell or organism. An expression vector can replicate as an autonomous structure, or alternatively can integrate, in whole or in part, into the host cell chromosomes or the nucleic acids of an organelle, or it is used as a shuttle for delivering foreign DNA to cells, and thus replicate along with the host cell genome. Thus, an expression vector is polynucleotides capable of replicating in a selected host cell, organelle, or organism, e.g., a plasmid, virus, artificial chromosome, nucleic acid fragment, and for which certain genes on the expression vector (including genes of interest) are transcribed and translated into a polypeptide or protein within the cell, organelle or organism; or any suitable construct known in the art, which comprises an “expression cassette.” In contrast, as described in the examples herein, a “cassette” is a polynucleotide containing a section of an expression vector of this invention. The use of the cassettes assists in the assembly of the expression vectors. An expression vector is a replicon, such as plasmid, phage, virus, chimeric virus, or cosmid, and which contains the desired polynucleotide sequence operably linked to the expression control sequence(s). A polynucleotide sequence is operably linked to an expression control sequence(s) (e.g., a promoter and, optionally, an enhancer) when the expression control sequence controls and regulates the transcription and / or translation of that polynucleotide sequence.

[0100] Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), the complementary (or complement) sequence, and the reverse complement sequence, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (see e.g., Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)). Because of the degeneracy of nucleic acid codons, one can use various different polynucleotides to encode identical polypeptides. As provided below, the table contains information about which nucleic acid codons encode which amino acids.

[0101] Amino acid Nucleic acid codons

[0102] In addition to the degenerate nature of the nucleotide codons which encode amino acids, alterations in a polynucleotide that result in the production of a chemically equivalent amino acid at a given site, but do not affect the functional properties of the encoded polypeptide, are well known in the art. “Conservative amino acid substitutions” are those substitutions that are predicted to interfere least with the properties of the reference polypeptide. In other words, conservative amino acid substitutions substantially conserve the structure and the function of the reference protein. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine or histidine, can also be expected to produce a functionally equivalent protein or polypeptide. As provided below, the table provides a list of exemplary conservative amino acid substitutions. Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and / or (c) the bulk of the side chain.

[0103] Amino Acids and Conservative Substitutes Oligonucleotides and polynucleotides that are not commercially available can be chemically synthesized e.g., according to the solid phase phosphoramidite triester method first described by Beaucage and Caruthers, Tetrahedron Letts. 22: 1859-1862 (1981), or using an automated synthesizer, as described in Van Devanter et al., Nucleic Acids Res. 12:6159- 6168 (1984). Other methods for synthesizing oligonucleotides and polynucleotides are known in the art. Purification of oligonucleotides is by either native acrylamide gel electrophoresis or by anion- exchange HPLC as described in Pearson & Reanier, J. Chrom. 255:137-149 (1983). Additional methods are known by those of ordinary skill in the art.

[0104] As used herein, the term “endogenous” refers to any material from or produced inside an organism, cell, tissue or system.

[0105] As used herein, the term “exogenous” or “heterologous” refers to any material introduced from or produced outside an organism, cell, tissue or system.

[0106] The term “recombinant” when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, organism, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein, or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells may express genes that are not found within the native (nonrecombinant or wild-type) form of the cell or express native genes that are otherwise abnormally expressed— over-expressed, under expressed or not expressed at all.

[0107] The terms “transgenic,” “transformed,” “transformation,” and “transfection” are similar in meaning to “recombinant.” “Transformation,” “transgenic,” and “transfection” refer to the transfer of a polynucleotide into the genome of a host organism or into a cell. Such a transfer of polynucleotides can result in genetically stable inheritance of the polynucleotides or in the polynucleotides remaining extra-chromosomally (not integrated into the chromosome of the cell). Genetically stable inheritance may potentially require the transgenic organism or cell to be subjected for a period of time to one or more conditions which require the transcription of some or all of the transferred polynucleotide in order for the transgenic organism or cell to live and / or grow. Polynucleotides that are transformed into a cell but are not integrated into the host’s chromosome remain as an expression vector within the cell. One may need to grow the cell under certain growth or environmental conditions in order for the expression vector to remain in the cell or the cell’s progeny. Further, for expression to occur the organism or cell may need to be kept under certain conditions. Host organisms or cells containing the recombinant polynucleotide can be referred to as “transgenic” or “transformed” organisms or cells or simply as “transformants,” as well as recombinant organisms or cells.

[0108] A genetically altered organism is any organism with any change to its genetic material, whether in the nucleus or cytoplasm (organelle). As such, a genetically altered organism can be a recombinant or transformed organism. A genetically altered organism can also be an organism that was subjected to one or more mutagens or the progeny of an organism that was subjected to one or more mutagens and has changes in its DNA caused by the one or more mutagens, as compared to the wild-type organism (i.e., organism not subjected to the mutagens). Also, an organism that has been bred to incorporate a mutation into its genetic material is a genetically altered organism.

[0109] The terms “approximately” and “about” refer to a quantity, level, value or amount that varies by as much as 30%, or in another embodiment by as much as 20%, and in a third embodiment by as much as 10% to a reference quantity, level, value or amount.

[0110] Cancer cells are often in the form of a tumor, but such cells may exist alone within an animal, or may be a non-tumorigenic cancer cell, such as a leukemia cell. As used herein, the term “cancer” includes premalignant as well as malignant cancers. Cancers include, but are not limited to, B cell cancer, e.g., multiple myeloma, Waldenstrom's macroglobulinemia, the heavy chain diseases, such as, for example, alpha chain disease, gamma chain disease, and mu chain disease, benign monoclonal gaminopathy, and melanomas, breast cancer, lung cancer bronchus cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer, cancer of the oral cavity or pharynx, liver cancer, kidney cancer, testicular cancer, biliary' tract cancer, small bowel or appendix cancer, salivary gland cancer, thyroid gland cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, , and the like.

[0111] A “pharmaceutical composition” or “pharmaceutical composition of the invention” refers to a 2’3’ -cGAMP, or a peptide according to Table 1, sometimes referred to as a compound of the invention or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof as an active ingredient, and at least one pharmaceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition comprises two or more pharmaceutically acceptable carriers and / or excipients. In other embodiments, the pharmaceutical composition further comprises at least one additional antibiotic, such as through a co-treatment. As used herein, a “pharmaceutically acceptable carrier” refers to a carrier or diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered composition of the invention. The pharmaceutical acceptable carrier may comprise any conventional pharmaceutical carrier or excipient. The choice of carrier and / or excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the carrier or excipient on solubility and stability, and the nature of the dosage form.

[0112] Suitable pharmaceutical carriers include inert diluents or fillers, water, and various organic solvents (such as hydrates and solvates). The pharmaceutical compositions may, if desired, contain additional ingredients such as flavorings, binders, excipients, and the like. Thus, for oral administration, tablets containing various excipients, such as citric acid may be employed together with various disintegrants such as starch, alginic acid and certain complex silicates and with binding agents such as sucrose, gelatin, and acacia. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed in soft and hard filled gelatin capsules. Nonlimiting examples of materials, therefore, include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration the active compound therein may be combined with various sweetening or flavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof.

[0113] The pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution suspension, for parenteral injection as a sterile solution, suspension, or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. Exemplary parenteral administration forms include solutions or suspensions of active compounds in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms may be suitably buffered, if desired. A pharmaceutical composition of the invention may be administered as single agents, for example a pharmaceutical composition of a compound of the invention, or a pharmaceutical composition of a compound of the invention, or may be administered in combination with an antibiotic, and preferably polymyxin family of antibiotic, such as polymyxin A or colistin. In some embodiments, the methods provided result in one or more of the following effects: (1) treating a MDR gram-negative bacterial infection in a subject, and preferably a polymyxin resistant Gramnegative bacteria; (2) inhibiting growth of gram-negative bacteria; (3) preventing infection of a MDR gram-negative bacterial infection in a subject; and (4) sensitizing or re-sensitizing a MDR gram-negative bacterial infection to an antibiotic and preferably polymyxin family of antibiotic, such as polymyxin A or colistin. Pharmaceutical compositions suitable for the delivery of one or more compounds of the invention as described herein, and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation can be found, for example, in 'Remington's Pharmaceutical Sciences', 19th Edition (Mack Publishing Company, 1995), the disclosure of which is incorporated herein by reference in its entirety.

[0114] The active compound can be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it can be enclosed in hard or soft shell gelatin capsules, or it can be compressed into tablets, or it can be incorporated directly with the food of the diet. For oral therapeutic administration, the active compound may be incorporated with excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparation can contain at least 0.1% of active compound. The percentage of the compositions and preparation can, of course, be varied and can conveniently be between about 1 to about 10% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Typical compositions or preparations according to the invention are prepared such that an oral dosage unit form contains from about 1 to about 1000 mg of active compound.

[0115] The tablets, troches, pills, capsules and the like can also contain the following: a binder such as gum tragacanth, acacia, com starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin can be added or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it can contain, in addition to materials of the above type, a liquid carrier. Various other materials can be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules can be coated with shellac, sugar or both. A syrup or elixir can contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compound can be incorporated into sustained-release preparations and formulation. In addition to the common dosage forms set out above, the compounds of the invention may also be administered by controlled release means and / or delivery devices capable of releasing the active ingredient (prenylation inhibitor) at the required rate to maintain constant pharmacological activity for a desirable period of time. Such dosage forms provide a supply of a drug to the body during a predetermined period of time and thus maintain drug levels in the therapeutic range for longer periods of time than conventional non-controlled formulations. Examples of controlled release pharmaceutical compositions and delivery devices that may be adapted for the administration of the active ingredients of the present invention are described in U.S. Pat. Nos.: 3,847,770; 3,916,899; 3,536,809; 3,598,123; 3,630,200; 4,008,719; 4,687,610; 4,769,027; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,566; and 5,733,566, the disclosures of which are hereby incorporated by reference.

[0116] Pharmaceutical compositions for use in the methods of the present invention may be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.

[0117] For example, a tablet may be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding, in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. The compound of the invention can also be administered parenterally. Solutions of the active compound as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersion can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

[0118] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It can be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacterial and fungi. The carrier can be a solvent of dispersion medium containing, for example, water, ethanol, polyol (e g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, e.g., sugars or sodium chloride. Prolonged absorption of the injectable compositions of agents delaying absorption, e g., aluminum monostearate and gelatin.

[0119] Sterile injectable solutions are prepared by incorporating the compound of the invention in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by fdtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.

[0120] The compounds of the invention can be administered to a mammal alone or in combination with pharmaceutically acceptable carriers, as noted above, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard pharmaceutical practice.

[0121] The physician can readily determine the dosage of the present therapeutic agents which will be most suitable for prophylaxis or treatment, and it will vary with the form of administration and the particular compound chosen, and also, it will vary with the particular patient under treatment. The physician will generally wish to initiate treatment with small dosages by small increments until the optimum effect under the circumstances is reached. The therapeutic dosage can generally be from about 0.1 to about 1000 mg / day, and preferably from about 10 to about 100 mg / day, or from about 0.1 to about 50 mg / Kg of body weight per day and preferably from about 0.1 to about 20 mg / Kg of body weight per day and can be administered in several different dosage units. Higher dosages, on the order of about 2x to about 4x, may be required for oral administration.

[0122] “A therapeutically effective amount” means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease. The “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated. “Treating” or “treatment” of a disease includes: (1) preventing the disease, i.e., causing the clinical symptoms of a bacterial infection not to develop in a mammal that may be exposed to or predisposed to the infection but does not yet experience or display symptoms of the infection; (2) inhibiting the disease, i.e., arresting or reducing the development of the infection or its clinical symptoms; or (3) relieving the disease, i.e., causing regression of the infection or its clinical symptoms.

[0123] When describing a chemical reaction, the terms “treating”, “contacting” and “reacting” are used interchangeably herein and refer to adding or mixing two or more reagents under appropriate conditions to produce the indicated and / or the desired product. It should be appreciated that the reaction which produces the indicated and / or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and / or the desired product. As used herein, the terms “those defined above” and “those defined herein” when referring to a variable incorporates by reference the broad definition of the variable as well as any narrow definitions, if any. As defined herein, with respect to any peptide or genetic sequence the terms “derived from” or “from” means directly isolated or obtained from a particular source or alternatively having identifying characteristics of a substance or organism isolated or obtained from a particular source. In the event that the “source” is an organism, “derived from” or “from” means that it may be isolated or obtained from the organism itself or from the medium used to culture or grow said organism.

[0124] The use of the word “a” or “an” when used in conjunction with the term ’’comprising” in the claims and / or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” The use of the term ”or” in the claims is used to mean “and / or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and / or.” Throughout this application, the term ’’about” is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects.

[0125] As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open- ended and do not exclude additional, unrecited elements or method steps.

[0126] The term ’’any combination thereof’ as used herein refers to all permutations and combinations of the listed items preceding the term. For example, “A, B, C, or any combinations thereof’ is intended to include at least one of A, B, C, AB, AC, BC, or ABC, and if order is important in a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing with this example, expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, AB, BBC, AAABCCCC, CBBAAA, CAB ABB, and so forth. The skilled artisan will understand that typically there is no limit on the number of items or terms in any combination, unless otherwise apparent from the context.

[0127] All of the compositions and / or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and / or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

[0128] TABLES

[0129] Table 1: Exemplary CD-NTase (Synthase) Enzymes of the Invention* * Included in Table 1 are orthologs of the proteins, as well as polypeptide molecules comprising an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%. 85%, 86%, 87%, 88%, 89%, 90%. 91%, 92%, 93%, 94%, 95%, 96%, 97%. 98%, 99%, 99.5% or more identity across their full length with an amino acid sequence of any SEQ ID NO listed in Table 1 , or a portion thereof. Such polypeptides can have a function of the full-length polypeptide as described further herein.

[0130] * Included in Table 1 are RNA nucleic acid molecules (e.g., thymines replaced with uredines), nucleic acid molecules encoding orthologs of the encoded proteins, as well as DMA or RNA nucleic acid sequences comprising a nucleic acid sequence having at least 80%, 81%, 82%, 83%. 84%. 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or more identity across their full length with the nucleic acid sequence ofany SEQ ID NO listed in Table 1, or a portion thereof. Such nucleic acid molecules can have a function of the full-length nucleic acid as described further herein.

Claims

CLAIMSWhat is claimed is1. A modified polypeptide that catalyzes biosynthesis of 2’3’-Cyclic-GMP-AMP (2’3’-cGAMP), wherein said modified polypeptide comprises an amino acid sequence having at least 70% identity to any one of the amino acid sequences according to SEQ ID NOs. 1-6, or a biologically active fragment thereof.

2. The modified polypeptide of claim 2, wherein the modified polypeptide catalyzes production of 2’3’-cGAMP in the absence of a ligand.

3. The modified polypeptide of claim 2, wherein the ligand is a double-stranded DNA.

4. The modified polypeptide of claim 1, wherein the 2’3’-cGAMP binds to and activates the Stimulator of Interferon Genes (STING) receptor.

5. The modified polypeptide of claim 4, wherein activation of STING occurs independently without the presence or activity of cyclic GMP-AMP synthase (cGAS).

6. The modified polypeptide of claim 1, wherein the polypeptide further comprising a heterologous polypeptide.

7. The modified polypeptide of claim 1„ wherein the heterologous polypeptide is selected from the group consisting of a signal peptide, a peptide tag, a dimerization domain, an oligomerization domain, an antibody, or an antibody fragment.

8. The modified polypeptide of claim 7, wherein the peptide tag is a thioredoxra. Maltose-binding protein (MBP), SUM02. Ghrtathione-S-Transferase (GST), calmodulin binding protein (CBP), protein C tag. Myc tag. HaloTag, HA tag, Flag tag, His tag, biotin tag, V5 tag, or OmpA signal sequence tag.

9. The modified polypeptide of claim 8, wherein the antibody fragment is an Fc domain.

10. The modified polypeptide of any one of claims 1-9, wherein the polypeptide is immobilized on an object selected from the group consisting of a cell, a metal, a resin, a polymer, a ceramic, a glass, a microelectrode, a graphitic particle, a bead, a gel a plate an array, and a capillary tube.

11. A pharmaceutical composition comprising the modified polypeptide of any one of claims 1-9, and a pharmaceutically acceptable carrier.

12. A pharmaceutical composition of claim 11, wherein said pharmaceutically acceptable carrier selected from the group consisting of excipients, and / or diluents.

13. An isolated nucleic acid molecule encoding the polypeptide of any one of claims 1-9.

14. An expression vector comprising a nucleotide sequence, operably linked to a promoter encoding the nucleic acid of claim 13.

15. A host cell transfected with the expression vector of claim 14.

16. A method of producing a polypeptide comprising culturing the host cell of claim 15 in an appropriate culture medium to, thereby, produce the polypeptide and / or 2’3’-cGAMP.

17. The method of claim 16, wherein the host cell is a bacterial cell or a eukaryotic cell.

18. The method of claim 17, wherein the bacterial cell comprises a probiotic bacterial cell.

19. The method of claim 16, wherein the host cell is genetically engineered to express a selectable marker.

20. The method of claim 16, further comprising the step of isolating the polypeptide from the medium or host cell.

21. The method of claim 16, further comprising the step of isolating the 2’3’-cGAMP produced by the polypeptide from the medium or host cell.

22. A pharmaceutical composition comprising the 2’3’-cGAMP produced method of claim 21, and a pharmaceutically acceptable carrier.

23. A method of treating a disease or condition comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 22 to a subject in need thereof, wherein the 2’3’-cGAMP activates the STING receptor in the subject.

24. A non-human animal model engineered to express a polypeptide of any one of claims 1-9.

25. The non-human animal model of claim 24, wherein the polypeptide is overexpressed.

26. The non-human animal model of claim 24, wherein the animal is a knock-in or a transgenic animal, and wherein the expression of cGAS has been disrupted or knocked-out.

27. The non-human animal model of claim 24, wherein the animal is a rodent.

28. A host cell genetically modified to express a nucleotide sequence encoding heterologous polypeptide that catalyzes biosynthesis of 2’3’-Cyclic-GMP-AMP (2’3’-cGAMP), wherein said polypeptide comprises an amino acid sequence having at least 70% identity to any one of the amino acid sequences according to SEQ ID NOs. 1-6, or a biologically active fragment thereof.

29. The host cell of claim 28, wherein the host cell is a bacterial cell or a eukaryotic cell.

30. The host cell of claim 29, wherein the bacterial cell comprises a probiotic bacterial cell.

31. A host cell genetically modified to express a nucleotide sequence encoding heterologous polypeptide that catalyzes biosynthesis of 2’3’-Cyclic-GMP-AMP (2’3’-cGAMP), wherein saidpolypeptide comprises an amino acid sequence having at least 70% identity he polypeptide of any one of claims 1-9, or a biologically active fragment thereof.

32. The host cell of claim 28, wherein the host cell is a bacterial cell or a eukaryotic cell.

33. The host cell of any of claims 28-32, and further comprising isolating the 2’3’-cGAMP produced by the polypeptide from host cell.

34. A pharmaceutical composition comprising the host cell of any of claims 28-32, and a pharmaceutically acceptable carrier.

35. A method of treating a disease or condition comprising, administering a therapeutically effective amount of the host cell of any of claims 28-34 to a subject in need thereof, wherein the 2’3’-cGAMP produced by the host cell activates the STING receptor in the subject.

36. A method of synthesizing 2’3’-cGAMP comprising contacting the polypeptide of any one of claims 1-9, or biologically active fragment thereof, with 2’3’-cGAMP nucleotide substrates.

37. The method of claim 39, wherein said 2’3’-cGAMP nucleotide substrates comprise adenosine triphosphate (ATP), and guanosine-5'-triphosphate (GTP).

38. The method of any one of claims 36-37, wherein contacting comprises the step of contacting in vitro, in vivo, or ex vivo.

39. The method of claim 38, wherein contacting comprises the step of contacting in a host cell.40 The method of any one of claims 36-39, further comprising purifying the synthesized 2’3’- cGAMP.

Citation Information

Patent Citations

  • ENGINEERED CYCLIC GMP-AMP SYNTHASE (cGAS) VARIANT ENZYMES

    US20220325285A1

  • CGAS / DNCV-like nucleotidyltransferases and uses thereof

    WO2020051197A1